Company intelligence / Profile preview

Collgard Biopharmaceuticals

Petah Tikva, Center District, Israelcollgard.com ↗

Ownership: Private
Development stage: Other

Overview

Collgard Biopharmaceuticals develops drug treatments that modulate tissue regeneration, primarily by targeting collagen pathways. Their lead compound, halofuginone hydrobromide, has been investigated for multiple indications including vascular restenosis and fibrosis. Some programs have reached clinical stages but the highest known phase for their main asset is discontinued in at least one indication (bladder cancer). The company maintains collaborations with major academic and clinical institutions.

Therapeutic areas: DermatologyOncologyCardiovascularOther
Modalities: Small moleculeCollagen inhibitor
Industry: Biotech

Partnerships

Mayo ClinicU.S. National Cancer Institute (NCI)European Organisation for Research and Treatment of Cancer (EORTC)Harvard Medical School

Beyond the preview

Go deeper on Collgard Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Collgard Biopharmaceuticals.